NF1 and glioblastoma: To determine whether Y102 was also effective in human tumor cells, the efficacy of Y102 was evaluated in two NF1-deficient human cell line models of glioblastoma, U87-MG and U251-MG, and an NF1-deficient MPNST cell line, sNF96.2.